Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALLO-605 |
| Synonyms | |
| Therapy Description |
ALLO-605 are allogeneic T-cells engineered to express a BCMA targeting chimeric antigen receptor (CAR), with TRAC and CD52 gene inactivation, which may lead to antitumor activity (Blood (2020) 136 (Supplement 1): 8). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALLO-605 | ALLO 605|ALLO605 | TNFRSF17 Immune Cell Therapy 27 | ALLO-605 are allogeneic T-cells engineered to express a BCMA targeting chimeric antigen receptor (CAR), with TRAC and CD52 gene inactivation, which may lead to antitumor activity (Blood (2020) 136 (Supplement 1): 8). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|